Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznany chłoniak nieziarniczy typu B (różne podtypy, np. rozlany chłoniak z dużych komórek B, chłoniak grudkowy, przewlekła białaczka limfocytowa)
- •Choroba, którą można zmierzyć obrazami (węzły chłonne lub guzy co najmniej 1,5 cm)
- •Choroba nawrotowa lub oporna po co najmniej dwóch poprzednich liniach leczenia, w tym terapiach skierowanych na białka CD19 lub CD20
- •Obecność białek CD19 lub CD20 na komórkach nowotworowych (potwierdzona po wcześniejszym leczeniu)
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG ≤ 2)
- •Prawidłowa funkcja nerek, wątroby i serca (opisana w kryteriach laboratoryjnych)
- •Zdolność do podpisania świadomej zgody na uczestnictwo w badaniu
✗ Disqualifies
- •Inny aktywny nowotwór (z wyjątkiem raka skóry bez cech czernicy lub raka in situ)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center
Cleveland, United States
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, United States
Trial contact
Paolo Caimi, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.